96 results on '"Mckay, R.R."'
Search Results
2. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
3. COVID-19 vaccination and breakthrough infections in patients with cancer
4. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
5. Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
6. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
7. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)
8. 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
9. CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
10. The Influence of Pelvic Lymph Node Dissection Volumes on Clinical Outcomes in NRG/RTOG 0534
11. 502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer
12. 501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
13. LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
14. 1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
15. LBA73 Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
16. 176P ERBB2 amplifications across sex, race, and cancer types
17. 1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
18. 1713P A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
19. 1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
20. 1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
21. 1653P Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
22. 1646P A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
23. 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
24. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
25. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
26. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
27. COVID-19 vaccination and breakthrough infections in patients with cancer
28. 683P Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
29. 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium
30. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
31. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
32. 284TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
33. 213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
34. 1908P Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
35. 1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
36. 1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
37. 2369P Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
38. 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
39. PCN31 REAL-WORLD TREATMENT PATTERNS OF RADIUM-223 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER RECEIVING CARE AT A US TERTIARY ONCOLOGY CENTER
40. A vegan form of life
41. Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours
42. Brigid Brophy's pro-animal forms
43. Effects of elevated cytoplasmic calcium and protein kinase C on endoplasmic reticulum structure and function in HEK293 cells
44. Body mass index and metastatic renal cell carcinoma: Clinical and biological correlations
45. Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial Carcinoma
46. Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm)
47. 986P - Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours
48. P138 - Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial Carcinoma
49. 854PD - Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm)
50. The application of Bayesian spectral analysis to optical sectioning using structured light imaging
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.